Acute cardiotoxicity during capecitabine treatment: a case report.
Capecitabine (Xeloda, Roche, Monza), a fluoropyrimidine carbamate, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumor. The drug has demonstrated activity in metastatic breast cancer, pancreatic cancer and colorectal cancer. In this case report the authors describe an unusually and reversible cardiac side effect which occurs to 39-year-old patient treated with capecitabine 2000 mg/m2/day for advanced gastric cancer. It is important to note that the safety data from clinical trials indicate that capecitabine has a toxicity profile typical of infused fluoropyrimidines. However, none of the studies described cardiac side effects.
Bertolini
A
A
Division of Medical Oncology, Ospedale di Sondrio, Italy. oncologia.sondrio@tiscalinet.it
Flumanò
M
M
Fusco
O
O
Muffatti
A
A
Scarinci
A
A
Pontiggia
G
G
Scopelliti
M
M
D000208:Acute Disease; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use; D004562:Electrocardiography / Q000187:drug effects; D005472:Fluorouracil / Q000031:analogs & derivatives; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D008297:Male; D013274:Stomach Neoplasms / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil